Is pemetinib now included in the scope of medical insurance reimbursement?

Pemigatinib (Pemigatinib) is a targeted drug used to treat specific cancers. It is currently on the market in China, mainly in the form of Pemigatinib tablets. Although the drug is already available on the market, as of now, pemetinib has not been included in the scope of domestic medical insurance reimbursement, which makes patients still face greater pressure on costs.

In the domestic market, pemetinib is mainly sold in two specifications: 4.5mg 14 tablets and 9mg 14 tablets. The price range is roughly between 2 to 5 RMB per box. Since it is not covered by medical insurance, patients need to bear the entire cost of the medicine themselves when purchasing it, so the cost of medication is relatively high. For patients, especially if they need to take it for a long time, such a price burden is a big challenge.

Compared with domestic prices, the price of pemetinib in overseas markets is more expensive. For example, taking the original drug of 13.5mg*14 tablets as an example, the price per box may be as high as 7 or more, and the price fluctuates due to factors such as exchange rates. In addition, patients can also purchase generic versions of pemetinib through overseas channels. The price is significantly lower and the drug ingredients are basically the same as the original drug.

Take the generic version of pemetinib produced by Lucius Pharmaceuticals in Laos as an example. The specification is 4.5mg*14 tablets. The price is only over RMB 700, which is very competitive. Comparing the price differences at home and abroad, some patients and medical institutions may consider importing generic drugs through legal channels to reduce the financial burden of medication. However, you still need to be cautious when purchasing to ensure that the medicine is from a legitimate source and meets quality standards.

Reference materials:https://go.drugbank.com/drugs/DB15102